Cosmos Health Inc. (NASDAQ:COSM – Free Report) – Stock analysts at Zacks Research cut their Q3 2026 EPS estimates for shares of Cosmos Health in a research note issued to investors on Wednesday, October 7th. Zacks Research analyst B. Sorensen now anticipates that the company will earn ($0.06) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Cosmos Health’s current full-year earnings is ($0.21) per share. Zacks Research also issued estimates for Cosmos Health’s Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.22) EPS.
Separately, Weiss Ratings upgraded Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has a consensus rating of “Sell”.
Cosmos Health Trading Up 9.5%
Shares of COSM opened at $0.38 on Wednesday. The company has a quick ratio of 0.92, a current ratio of 1.05 and a debt-to-equity ratio of 0.15. The firm’s fifty day simple moving average is $0.28 and its two-hundred day simple moving average is $0.28. Cosmos Health has a 12 month low of $0.16 and a 12 month high of $1.26.
Cosmos Health (NASDAQ:COSM – Get Free Report) last posted its quarterly earnings data on Tuesday, August 18th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The company had revenue of $19.32 million during the quarter, compared to analysts’ expectations of $18.99 million. Cosmos Health had a negative net margin of 33.08% and a negative return on equity of 56.88%.
Hedge Funds Weigh In On Cosmos Health
A hedge fund recently bought a new position in Cosmos Health stock. BlackRock Inc. acquired a new position in shares of Cosmos Health Inc. (NASDAQ:COSM – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 267,797 shares of the company’s stock, valued at approximately $49,000. BlackRock Inc. owned 0.45% of Cosmos Health as of its most recent SEC filing. 12.61% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Cosmos Health news, CEO Grigorios Siokas bought 349,825 shares of the stock in a transaction on Thursday, July 30th. The stock was acquired at an average cost of $0.20 per share, for a total transaction of $69,965.00. Following the completion of the acquisition, the chief executive officer owned 14,597,917 shares in the company, valued at $2,919,583.40. This trade represents a 2.46% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders own 26.15% of the company’s stock.
Cosmos Health Company Profile
Cosmos Health Inc is a global healthcare group that develops, markets and distributes pharmaceutical, nutraceutical and wellness products. The company serves consumers, healthcare professionals and commercial partners through a portfolio that includes prescription and over-the-counter medicines, dietary supplements, vitamins and other health-related products.
Cosmos Health markets proprietary nutraceutical brands, including Sky Premium Life, and offers products across categories such as vitamins, minerals, sports nutrition and general wellness.
Featured Stories
- Five stocks we like better than Cosmos Health
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
